Über uns

Solgate   is a new research-driven biopharmaceutical startup that develops drugs targeting solute carrier (SLC) proteins, the largest family of membrane transporters. By modulating the function of the “gates” to cellular metabolism, Solgate aims to address unmet medical needs  in neurological diseases, in metabolic disorders and in cancer. Solgate is located in the newly established IST Park, a space housing a growing community of technology startups and biotech companies, adjacent to IST Austria in Klosterneuburg, near Vienna.